SIETES :: 93213 citas

Resultados de la búsqueda por FASE II REFINAR BÚSQUEDA

1.

Thomas K. Sanofi and GlaxoSmithKline delay plans for a trial after experimental vaccine fails in some older patients.. N Y Times (Print) 2020:15 de diciembre. [Ref.ID 103817]

2.

Keech C, Albert G, Cho I, Robertson A, Reed P, Neal.S, Plested JS, Zhu M, Cloney-Clark S, Zho H, Smith G, Patel N, et al.. Phase 1–2 trial of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine. N Engl J Med 2020;383:2320-32. [Ref.ID 103813]

3.

Monk PD, Marsden RJ, Tear VJ, Brookes J, Batten TN, Mankowski M, Gabbay FJ, Davies DE, Holgate ST, Ho L-P, Clark T, Djukanovic R, Wilkinson TMA, on behalf of the Inhaled Interferon Beta COVID-19 Study Group. . The Lancet Respiratory Medicine 0:1. [Ref.ID 103778]

4.

Walsh EE, Frenck Jr RW, Falsey AR, Kitchin N, Absalon J, Gurtman A, Lockhart S, Neuzil K, Mulligan MJ, Bailey R, Swanson KA, Li P, et al.. Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates. N Engl J Med 2020;383:17 de diciembre. [Ref.ID 103749]

5.

Poland GA, Ovsyannikova IG, Kennedy RB. SARS-CoV-2 immunity: review and applications to phase 3 vaccine candidates. Lancet 2020;396:13 de octubre. [Ref.ID 103744]

6.

Logunov DY, Dolzhikova IV, Tukhvatulin AI, Shcheblyakov DV. Safety and efficacy of the Russian COVID-19 vaccine: more information needed – Authors’ reply. Lancet 2020;396:3 de octubre. [Ref.ID 103738]

7.

Bucci E, Andreev K, Björkman A, Calogero RA, Carafoli E, Carninci P, Castagnoli P, Cossarizza A, Musini C, Guerin P, Lipworth B, Sbardella G, Stocki T, Tuosto L, van Tulleken C, Viola A. Safety and efficacy of the Russian COVID-19 vaccine: more information needed. Lancet 2020;396:21 de septiembre. [Ref.ID 103737]

8.

Logunov DY, Dolzhikova IV, Zubkova OV, Tukhvatulin AI, Shcheblyakov DV, Dzharullaeva AS, et al.. Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia. Lancet 2020;396:26 de septiembre. [Ref.ID 103724]

9.

Schachar RA, Schachar IH. A SARS-CoV-2 mRNA vaccine — Preliminary report. N Engl J Med 2020;383:19 de agosto. [Ref.ID 103706]

10.

Parsons L. Novavax reports promising phase 1 results for coronavirus vaccine. PMLiVE 2020:5 de agosto. [Ref.ID 103702]

11.

Parsons L. AZ/Oxford’s COVID-19 vaccine proves promising in early trials. Vaccine candidate produced robust immune response. PMLiVE 2020:21 de julio. [Ref.ID 103692]

12.

Zhu F-C, Guan X-H, Li Y-H, Huang J-Y, Jiang T, Hou L-H, et al.. Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet 2020;396:20 de julio. [Ref.ID 103691]

13.

Folegatti PM, Ewer KJ, Aley PK, Angus B, Becker S, Belij-Rammerstorfer S, et al.. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. Lancet 2020;396:20 de julio. [Ref.ID 103690]

14.

Jackson LA, Anderson EJ, Rouphael NG, Roberts PC, Makhene M, Coler RN, McCullough P, Chappell JD, Denison MR, Stevens LJ, Pruijssers AJ, McDermott A, et al. for the mRNA-1273 Study Group. An mRNA vaccine against SARS-CoV-2 — Preliminary report. N Engl J Med 2020;383:12 de noviembre. [Ref.ID 103684]

15.

Mullard A. COVID-19 vaccine development pipeline gears up. Lancet 2020;395:6 de junio. [Ref.ID 103658]

16.

PMG Group. Imperial College London pledges low-cost access to COVID-19 vaccine. PMLiVE 2020:8 de junio. [Ref.ID 103657]

17.

PMGroup. AZ secures capacity for one billion coronavirus vaccine doses. Initial agreement to supply 400 million doses of Oxford University’s vaccine. PMLiVE 2020:21 de mayo. [Ref.ID 103648]

18.

Taylor P. Novavax COVID-19 vaccine bags record $384m funding from CEPI. PMLiVE 2020:12 de mayo. [Ref.ID 103623]

19.

Corbella J. La primera vacuna de la Covid ensayada en personas muestra eficacia. La Vanguardia 2020:19 de mayo. [Ref.ID 103619]

20.

Samper E. Lo que el dinero no puede acelerar: ¿Por qué requiere tanto tiempo conseguir una vacuna contra el coronavirus? . eldiario.es 2020:9 de mayo. [Ref.ID 103617]